ArticleJournal of gastroenterology2023
Prognostic role of detailed colorectal location and tumor molecular features: analyses of 13,101 colorectal cancer patients including 2994 early-onset cases.
Open access · greenAbstract read
In one paragraph
Article in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- A comparison of overall survival from early-onset and late-onset colorectal cancer stratified by TNM stage: a systematic review.British journal of cancer · 2026Pooled it
- The emperor has no clothes-the need for standardized anatomical segment definitions in the management of colon cancer.International journal of colorectal disease · 2025Pooled it
- Prior cholecystectomy may identify a biologically aggressive subset of RAS-mutated proximal colon cancer: A 13-year retrospective cohort study.Surgery today · 2026Article
- Survival of Colon Cancer in a Population-Based Cohort Study: A Comprehensive Analysis of Location of the Primary Tumor.Cancer medicine · 2026Article
- Differential Prognostic Impact of Prior Cholecystectomy Between Proximal and Distal Colorectal Cancer: A 12-Year Retrospective Cohort Study of 3487 Consecutive Patients.Annals of gastroenterological surgery · 2026Article
- Primary Anastomosis Versus Hartmann's Procedure in Obstructing Colorectal Cancer: A Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2025Article
- Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers.Cancers · 2025Review
- Appendectomy and Long-term Colorectal Cancer Incidence, Overall and by Tumor Fusobacterium nucleatum Status.Annals of surgery · 2025Article
- Development and validation of predictive nomograms for survival in early-onset colon cancer patients with II-III stage across various tumor sites.Translational cancer research · 2025Article
- Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies.NPJ precision oncology · 2025Review
- Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer.Journal of inflammation research · 2025Article
- Single-cell and Multi-omics Analysis Confirmed the Signature and Potential Targets of Cuproptosis in Colorectal Cancer.Journal of Cancer · 2025Article
- The epigenetic influence of diet-induced gut microbiome changes in precision nutrition - a systematic review.Gastroenterology and hepatology from bed to bench · 2025Review
- The Cancer Spectrum Theory.Cancer discovery · 2024Article
- A Novel DNA Variant inInternational journal of molecular sciences · 2024Article
- Development and validation of a clinical prognostic model for BRAF V600E-mutated colorectal cancer patients based on pathological stage, microsatellite status, and primary tumor site.Frontiers in oncology · 2024Article
- Prognostic potential of whole exome sequencing in the clinical management of metachronous colorectal cancer liver metastases.Cancer cell international · 2023Article
- Histopathology and levels of proteins in plasma associate with survival after colorectal cancer diagnosis.British journal of cancer · 2023Article
- Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment.Journal of personalized medicine · 2023Review
- Bayesian risk prediction model for colorectal cancer mortality through integration of clinicopathologic and genomic data.NPJ precision oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 20 institutions in 9 countries.
Tomotaka Ugai *Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA. tugai@bwh.harvard.edu.
Naohiko Akimoto *Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA.
Koichiro Haruki *Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA.
Tabitha A Harrison *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Yin CaoDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
Conghui QuPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Andrew T ChanClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Peter T CampbellDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Daniel D BuchananColorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australia.
Amanda J CrossDepartment of Epidemiology and Biostatistics, Imperial College London, Norfolk Place, London, UK.
Brenda DiergaardeDepartment of Human Genetics, Graduate School of Public Health, University of Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Steven J GallingerLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Marc J GunterNutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Sophia HarlidDepartment of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.
Akihisa HidakaPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Michael HoffmeisterDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Li HsuPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Mark A JenkinsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Yi LinPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Roger L MilneCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Victor MorenoUnit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Polly A NewcombPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Reiko NishiharaProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA.
Mireia Obon-SantacanaUnit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Rish K PaiDepartment of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Lori C SakodaPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Robert E SchoenDepartment of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Martha L SlatteryDepartment of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Wei SunPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Efrat L AmitayDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Elizabeth AlwersDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stephen N ThibodeauDivision of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Amanda E TolandDepartments of Cancer Biology and Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Bethany Van GuelpenDepartment of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.
Syed H ZaidiOntario Institute for Cancer Research, Toronto, ON, Canada.
John D PotterPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marios GiannakisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mingyang SongDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jonathan A Nowak *Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA.
Ulrike Peters *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Amanda I Phipps *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Shuji Ogino *Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA. sogino@bwh.harvard.edu.ORCID 0000-0002-3909-2323
Brigham and Women's Hospital · USFred Hutch Cancer Center · USGerman Cancer Research Center · DEUniversity of Washington · USBellvitge University Hospital · ESBroad Institute · USThe University of Melbourne · AUUmeå University · SEAlbert Einstein College of Medicine · USCentre international de recherche sur le cancer · FRDana-Farber Cancer Institute · USHarvard University · USImperial College London · GBKaiser Permanente · USMayo Clinic · USMayo Clinic in Arizona · USMount Sinai Hospital · CANational Institutes of Health · USOntario Institute for Cancer Research · CAThe Ohio State University · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8MValidity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI FUCHS, CHARLES S · 1991 to 2009
$41.8MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MMolecular pathological epidemiology of colorectal cancerU01CA137088 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2009 to 2018
$21.8MCancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0MData sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8MSEATTLE FAMILIAL COLORECTAL CANCER REGISTRYU01CA074794 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEWCOMB, POLLY A · 1997 to 2007
$14.1MONTARIO REGISTRY FOR STUDIES OF FAMILIAL COLON CANCERU01CA074783 · NCI · CANCER CARE ONTARIO · PI GALLINGER, STEVEN · 1997 to 2008
$12.5MCancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5MDIET, ACTIVITY &REPRODUCTION--RISKS FOR RECTAL CANCERR01CA048998 · NCI · UNIVERSITY OF UTAH · PI SLATTERY, MARTHA L · 1991 to 2012
$7.9MCancer Research UK 14136 to EPIC-NorfolkCancer Research UK 25004Cancer Research UK 27140Cancer Research UK C570/A16491Cancer Research UK C8221/A19170 to EPIC-OxfordCancer Research UK UK C10674/A27140Medical Research Council 1000143 to EPIC-NorfolkMedical Research Council MR/M012190/1Medical Research Council MR/M012190/1 to EPICOxfordNCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA016058NCI NIH HHS R00 CA215314NCI NIH HHS R01 CA048998NCI NIH HHS R01 CA067941NCI NIH HHS R01 CA076366NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA248857NCI NIH HHS R01 CA263776NCI NIH HHS R35 CA197735NCI NIH HHS U01 CA067941NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA084968NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA167551NCI NIH HHS U01 CA167552NCI NIH HHS U24 CA074783NCI NIH HHS U24 CA074794NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA186107NIH HHS CA16058NIH HHS CA67941NIH HHS P01 CA055075NIH HHS P01 CA087969NIH HHS R00 CA215314NIH HHS R01 CA076366NIH HHS R01 CA137178NIH HHS R01 CA151993NIH HHS R01 CA248857NIH HHS R01 CA48998NIH HHS R35 CA197735NIH HHS S10 OD028685NIH HHS U01 CA074794NIH HHS U01 CA137088NIH HHS U01 CA167551NIH HHS U01 CA167552NIH HHS U01/U24 CA074783NIH HHS U24 CA074794NIH HHS UM1 CA167552NIH HHS UM1 CA186107Wellcome Trust 209057World Health Organization 001
Abstract
backgroundThe pathogenic effect of colorectal tumor molecular features may be influenced by several factors, including those related to microbiota, inflammation, metabolism, and epigenetics, which may change along colorectal segments. We hypothesized that the prognostic association of colon cancer location might differ by tumor molecular characteristics.
methodsUtilizing a consortium dataset of 13,101 colorectal cancer cases, including 2994 early-onset cases, we conducted survival analyses of detailed tumor location stratified by statuses of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and KRAS and BRAF oncogenic mutation.
resultsThere was a statistically significant trend for better colon cancer-specific survival in relation to tumor location from the cecum to sigmoid colon (P
conclusionsBoth detailed colonic location and tumor molecular features need to be accounted for colon cancer prognostication to advance precision medicine. Our study indicates the important role of large-scale studies to robustly examine detailed colonic subsites in molecular oncology research.
Indexed as
Colonic NeoplasmsColorectal NeoplasmsCpG IslandsDNA MethylationHumansMicrosatellite InstabilityMutationPhenotypePrognosisProto-Oncogene Proteins B-rafProto-Oncogene Proteins B-rafBiogeographyEpigeneticsMismatch repairMolecular pathological epidemiologyYoung-onset cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.